FDA approves new treatment for relapsed follicular lymphoma

follicular lymphoma fda treatment

On Sept. 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies.

Read More at FDA.gov

LEAVE A REPLY

Please enter your comment!
Please enter your name here